MedTrace Logo

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

NCT05134337 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-01-09

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.

Conditions

  • Healthy Volunteers

Interventions

DRUG

LOXO-305

Oral LOXO-305

DRUG

Itraconazole

Oral itraconazole

DRUG

Rifampin

Oral rifampin

Sponsors & Collaborators

  • Loxo Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Renée Ward, MD, PhD · Loxo Oncology, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2020-10-30
Completion
2020-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05134337 on ClinicalTrials.gov